Thermo Fisher stock rises 3% on second quarter earnings beat

Investing.com--On Thursday, Thermo Fisher Scientific Inc. (NYSE: TMO) reported second quarter results that exceeded analyst expectations, as the company demonstrated strengthening customer activity across its end markets.

The life sciences tools maker’s shares went up 3.14% in pre-market trading following the release.

The company posted adjusted earnings per share of $6.03 for the quarter ended June 27, 2026, beating the analyst consensus of $5.72 by $0.31.

Revenue grew 10% to $11.99 billion, surpassing the $11.71 billion estimate and marking a 10% increase from $10.85 billion in the same quarter last year. Organic revenue growth was 5%.

"We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the power of our PPI Business System," said Marc N. Casper, chairman and chief executive officer. "Our end markets continue to strengthen and we’re making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain."

GAAP diluted EPS grew 9% to $4.68, while adjusted operating margin expanded to 22.8% from 21.9% in the prior year period.

The company’s Laboratory Products and Biopharma Services segment generated $6.69 billion in revenue, representing 55.8% of total sales.

During the quarter, Thermo Fisher launched next-generation Orbitrap platforms with AI-driven analytics and opened a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts.

The company also repurchased $1.0 billion of stock and announced the divestiture of its microbiology business.

The company plans to provide updated 2026 financial guidance during its earnings conference call.

You May Also Be Interested In

• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
• Investing.com’s stocks of the week
• Ulta Beauty beats estimates as sales rise, shares gain